Skip Ribbon Commands
Skip to main content

Terumo Medical Corporation Celebrates Opening of State-of-the-art New Product Development Lab at Its Elkton, MD, Manufacturing Facility

New 18,250 sq. ft. space combines manufacturing and development capabilities in one location for maximum efficiency and speed to market.

3/02/2011 - Elkton, MD, USA

​Elkton, MD. (February 3, 2011) – Terumo Medical Corporation, a U.S.-based subsidiary of Terumo Corporation, today held a celebration marking the formal opening of a 18,250 square foot (sq.ft.) renovation at its Elkton manufacturing facility. The upgrade features a new, state-of-the-art product development laboratory that the company believes will be instrumental in delivering an estimated 50 percent growth in sales over the next five years.

Opened in 1972, Terumo's Elkton manufacturing facility employs 300 Associates and produces many of the company's industry leading medical devices including key products such as the Pinnacle® Introducer Sheath, Pinnacle® Destination® Guiding Sheath, Terumo® Insulin Syringe, Surflo® I.V. Catheter, the TSCD® Sterile Tubing Welder and Trucise Total System®. The upgraded facility combines manufacturing and new product development in the same geographic location, which will streamline introductions, while saving time and resources.

"The opening of this renovated facility is part of a longer-term strategy to reinvent the Elkton plant from producing commoditized products to highly competitive, technologically advanced devices that add superior value to our clients and help to drive the efficiency of healthcare. The synergies derived by co-locating our development and manufacturing teams fosters a climate of innovation all in support of our goal to drive competitive advantage," says Harry MacArthur, Vice President, Manufacturing, Terumo Medical Corporation. "Our very capable and skilled workforce is already maximizing the upgraded facility by actively engaging in two, new major product launches planned over the next year."

In addition to greatly enhanced speed to market, the facility will offer unprecedented opportunity for Terumo to work onsite with its U.S. physician customer base to incorporate their critical feedback into the development cycle on a much faster basis.

"The opening of our new Elkton product development lab ensures we can develop, prototype, and manufacture high-quality, unique medical devices faster, and more efficiently than ever before; allowing us to more effectively meet the dynamic needs of our U.S. customer base." said Juichi (Jim) Takeuchi, President and CEO, Terumo Medical Corporation. "While the immediate focus will be on expanding the interventional, transfusion and safety medical device offering, it is with great expectation that our product portfolio will evolve into new frontiers."

For more information about the Elkton facility, contact Rosemarie Mendes, Senior Marketing Communications Manager, at 732.302.4903.

Terumo Medical Corporation

Founded in 1972 as a Terumo Corporation subsidiary, Terumo Medical Corporation (TMC) develops, manufactures, and markets high-quality medical devices used in a broad range of applications in numerous healthcare markets. TMC manufactures a broad portfolio of needles and syringes, entry-site management products, and a line of sterile connection devices used in hospitals and blood banks worldwide.

Terumo Corporation

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with $3.0 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the healthcare market and by responding to the needs of healthcare providers and the people they serve. Terumo Corporation's shares
are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.

Press Contact

Robert J. Murphy
Peter Collins
The Storch-Murphy Group
(908) 276-0777